| Identification | Back Directory | [Name]
5H-Imidazo[1',2':1,2]pyrrolo[3,4-c]pyridin-5-one, 9b-(4-chlorophenyl)-1,2,3,9b-tetrahydro-1-(3-pyridinylcarbonyl)-, (9bS)- | [CAS]
1646857-24-0 | [Synonyms]
BTA9881
AZD9639
AZD-9639
BTA 9881
BTA-9881
MEDI-564
BTA 9881,BTA9881
5H-Imidazo[1',2':1,2]pyrrolo[3,4-c]pyridin-5-one, 9b-(4-chlorophenyl)-1,2,3,9b-tetrahydro-1-(3-pyridinylcarbonyl)-, (9bS)- | [Molecular Formula]
C21H15ClN4O2 | [MOL File]
1646857-24-0.mol | [Molecular Weight]
390.82 |
| Chemical Properties | Back Directory | [Boiling point ]
636.0±55.0 °C(Predicted) | [density ]
1.51±0.1 g/cm3(Predicted) | [solubility ]
DMSO:0.0(Max Conc. mg/mL);0.0(Max Conc. mM) | [pka]
3.46±0.10(Predicted) |
| Hazard Information | Back Directory | [Uses]
BTA-9881 (MEDI-564) is a RSV inhibitor, with an EC50: 48 nM, 59 nM and 160 nM for RSV A2, RSV Long, and RSV B1. BTA-9881 has favorable pharmacokinetics property[1]. | [References]
[1] Bond S, et al. 1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: identification of BTA9881 as a preclinical candidate. Bioorg Med Chem Lett. 2015 Feb 15;25(4):976-81. DOI:10.1016/j.bmcl.2014.11.024 |
|
|